Screening mammography is recommended for women 50 to 69 years of age because of its proven efficacy and reasonable cost-effectiveness.
Extending screening recommendations to include women 40 to 49 years of age remains controversial.
To compare the cost-effectiveness of screening mammography in women of different age groups.
Cost-effectiveness analysis done using Markov and Monte Carlo models.
General population of women 40 years of age and older.
Biennial screening from 50 to 69 years of age was compared with no screening.
Screening done every 18 months from ages 40 to 49 years, followed by biennial screening from ages 50 to 69 years, was compared with biennial screening from ages 50 to 69 years.
Life-expectancy, costs, and incremental cost-effectiveness.
Screening women from 50 to 69 years of age improved life expectancy by 12 days at a cost of $704 per woman, resulting in a cost-effectiveness ratio of $21 400 per year of life saved.
Extending screening to include women 40 to 49 years of age improved life expectancy by 2.5 days at a cost of $676 per woman.
The incremental cost-effectiveness of screening women 40 to 49 years of age was $105 000 per year of life saved. (...)
Mots-clés Pascal : Carcinome, Glande mammaire, Etude comparative, Mammographie, Dépistage, Critère âge, Rapport coût bénéfice, Modèle Markov, Prévention, Evaluation, Facteur efficacité, Femelle, Homme, Tumeur maligne, Glande mammaire pathologie, Radiodiagnostic, Economie santé
Mots-clés Pascal anglais : Carcinoma, Mammary gland, Comparative study, Mammography, Medical screening, Age criterion, Cost benefit ratio, Markov model, Prevention, Evaluation, Effectiveness factor, Female, Human, Malignant tumor, Mammary gland diseases, Radiodiagnosis, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0041582
Code Inist : 002B20E02. Création : 17/04/1998.